March 31, 2023

Volume XIII, Number 90

Advertisement
Advertisement

March 31, 2023

Subscribe to Latest Legal News and Analysis

March 30, 2023

Subscribe to Latest Legal News and Analysis

March 29, 2023

Subscribe to Latest Legal News and Analysis

March 28, 2023

Subscribe to Latest Legal News and Analysis
Advertisement

SEC’s Proposed Amendments to Financial Disclosure Requirements in Regulation S-K and New Guidance on Metrics in MD&A

On January 30, 2020, the Securities and Exchange Commission (SEC) announced its proposal to amend certain financial disclosure requirements in Regulation S-K for the purpose of eliminating duplicative disclosures and modernizing and enhancing disclosures in Management’s Discussion and Analysis (MD&A) for the benefit of investors, while reducing compliance burdens and costs for companies. This proposal is part of a comprehensive evaluation of the SEC’s disclosure requirements that was recommended in the SEC staff’s Report on Review of Disclosure Requirements in Regulation S-K in December 2013, which was mandated by Section 108 of the Jumpstart Our Business Startups Act of 2012. 

The proposed amendments would eliminate Item 301 (selected financial data) and Item 302 (supplementary financial data) due to their duplicative nature, and amend Item 303 (management’s discussion and analysis) with the main changes summarized as below:

  • Add a new Item 303(a), Objective (and recaption current Item 303(a), Full fiscal years as Item 303(b)), to include much of the substance in Instructions 1, 2 and 3 of the current Item 303(a), which state the principal objectives of MD&A for both full fiscal years and interim periods. This proposed amendment is intended to provide clarity to companies as they consider what information to discuss and analyze in MD&A, in order to provide both a historical and prospective analysis of their financial condition and results of operations, with particular emphasis on their prospects for the future;

  • Replace Item 303(a)(4), Off-balance sheet arrangements, with a principles-based instruction to discuss off-balance sheet arrangements in the broader context of MD&A. Under the new instruction, companies would be required to discuss commitments or obligations, including contingent obligations, arising from arrangements with unconsolidated entities or persons that have, or are reasonably likely to have, a material current or future effect on such company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, cash requirements, or capital resources, even when the arrangement results in no obligation being reported in the company’s consolidated balance sheets;

  • Eliminate Item 303(a)(5), Tabular disclosure of contractual obligations, given the overlap with information required in the financial statements and to promote the principles-based nature of MD&A;

  • Add a new Item 303(b)(4), Critical accounting estimates, to clarify and codify existing SEC guidance in this area; 

  • Eliminate current Item 303(c), Safe harbor, in light of the proposed replacement of Item 303(a)(4) and elimination of Item 303(a)(5); and

  • Amend current Item 303(b), Interim periods (recaptioned as Item 303(c)), to provide flexibility by allowing companies to compare their most recently completed quarter to either the corresponding quarter of the prior year (as is currently required) or to the immediately preceding quarter.

The proposal also includes certain conforming amendments, including to Form 20-F and Form 40-F, applicable to financial disclosures provided by foreign private issuers.

The proposal will have a 60-day public comment period following its publication in the Federal Register. We will continue to follow developments in this matter.

Concurrent with the proposal, the SEC also issued guidance on key performance indicators and metrics in MD&A, which says that when companies disclose key performance indicators and metrics in MD&A, they may also want to consider whether additional disclosures are necessary in order to make the presentation of the indicators and metrics, in light of the circumstances under which they are presented, not misleading. In addition, the SEC reminds companies 1) of the requirements in Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934 to maintain effective disclosure controls and procedures and 2) that companies may want to consider whether they have effective controls and procedures in place to process information related to the disclosure of key performance indicators and metrics in a manner that ensures consistency as well as accuracy.

Copyright © 2023 Robinson & Cole LLP. All rights reserved.National Law Review, Volume X, Number 38
Advertisement
Advertisement
Advertisement

About this Author

Eric Kogan Business Transaction Attorney Robinson+Cole
Partner

Eric Kogan is co-chair of the firm's Business Transactions Group and a member of its Managing Committee. He represents clients in a broad range of corporate, strategic, financial, and commercial transactions, and he provides business counseling for corporate clients as well as for entrepreneurs. In the 2019 Edition of CHAMBERS USA: America's Leading Lawyers for Business, Eric is described by clients as "a consummate professional" who "rolls up his sleeves and helps us achieve our objective." Over the past five years, he has led more than 30 transactions with an...

203-462-7584
Leslie Levinson Health Business Attorney
Partner

Leslie Levinson is co-chair of the firm's Transactional Health Law Group and a member of both the Health Law and Business Transaction Groups. He has represented private and public businesses throughout his more than 30-year career. Although Les maintains an active business law practice, he concentrates on the transactional, regulatory, and compliance representation of health care and life science clients, including home care and hospice companies, physician practices, hospitals, information technology and medical device companies, health care equipment providers, and health care investors...

212-451-2979
Anna Jinhua Wang Markets and Securities Attorney
Partner

Anna Jinhua Wang, a member of the firm’s Business Transactions Group, assists clients with capital markets and securities law, mergers and acquisitions, and general corporate matters. She is fluent in Mandarin and Cantonese.

Capital Markets and Securities

Anna has a decade of experience helping public and private companies in capital market and securities-related matters. She represents clients across a range of industries, from emerging to established companies, and she helps them identify and secure sources of capital. She advises clients on capital...

212-451-2942